203 related articles for article (PubMed ID: 9397401)
21. Ischemic ventricular arrhythmias during heart failure: a canine model to replicate clinical events.
Issa ZF; Rosenberger J; Groh WJ; Miller JM; Zipes DP
Heart Rhythm; 2005 Sep; 2(9):979-83. PubMed ID: 16171754
[TBL] [Abstract][Full Text] [Related]
22. Effect of a 'vagomimetic' atropine dose on canine cardiac vagal tone and susceptibility to sudden cardiac death.
Halliwill JR; Billman GE; Eckberg DL
Clin Auton Res; 1998 Jun; 8(3):155-64. PubMed ID: 9651665
[TBL] [Abstract][Full Text] [Related]
23. Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation.
Friedrichs GS; Abreu JN; Driscoll EM; Borlak J; Lucchesi BR
J Cardiovasc Pharmacol; 1998 Jan; 31(1):56-66. PubMed ID: 9456278
[TBL] [Abstract][Full Text] [Related]
24. 5-hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death.
Friedrichs GS; Abreu JN; Black SC; Chi L; Lucchesi BR
Eur J Pharmacol; 1996 Jun; 306(1-3):99-106. PubMed ID: 8813621
[TBL] [Abstract][Full Text] [Related]
25. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction.
Vanoli E; De Ferrari GM; Stramba-Badiale M; Hull SS; Foreman RD; Schwartz PJ
Circ Res; 1991 May; 68(5):1471-81. PubMed ID: 2019002
[TBL] [Abstract][Full Text] [Related]
26. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction.
De Ferrari GM; Salvati P; Grossoni M; Ukmar G; Vaga L; Patrono C; Schwartz PJ
J Am Coll Cardiol; 1993 Jul; 22(1):283-90. PubMed ID: 8509552
[TBL] [Abstract][Full Text] [Related]
27. HBI-3000 prevents secondary sudden cardiac death.
Lee JY; Lucchesi BR
J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):453-9. PubMed ID: 23615576
[TBL] [Abstract][Full Text] [Related]
28. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death.
Friedrichs GS; Chi L; Gralinski MR; Black SC; Basler GC; Mu DX; Pewitt SR; Johnson CR; Lucchesi BR
J Cardiovasc Pharmacol; 1995 Feb; 25(2):314-23. PubMed ID: 7752658
[TBL] [Abstract][Full Text] [Related]
29. Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence.
Leaf A; Kang JX
J Intern Med; 1996 Jul; 240(1):5-12. PubMed ID: 8708597
[TBL] [Abstract][Full Text] [Related]
30. n-3 fatty acids prevent whereas trans-fatty acids induce vascular inflammation and sudden cardiac death.
Siddiqui RA; Harvey KA; Ruzmetov N; Miller SJ; Zaloga GP
Br J Nutr; 2009 Dec; 102(12):1811-9. PubMed ID: 19822033
[TBL] [Abstract][Full Text] [Related]
31. Cocaine-induced ventricular fibrillation: protection afforded by the calcium antagonist verapamil.
Billman GE; Hoskins RS
FASEB J; 1988 Nov; 2(14):2990-5. PubMed ID: 3181653
[TBL] [Abstract][Full Text] [Related]
32. Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids.
Leaf A
Fundam Clin Pharmacol; 2006 Dec; 20(6):525-38. PubMed ID: 17109646
[TBL] [Abstract][Full Text] [Related]
33. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
Black SC; Butterfield JL; Lucchesi BR
J Cardiovasc Pharmacol; 1993 Dec; 22(6):810-8. PubMed ID: 7509898
[TBL] [Abstract][Full Text] [Related]
34. Selective late sodium current blockade with GS-458967 markedly reduces ischemia-induced atrial and ventricular repolarization alternans and ECG heterogeneity.
Bonatti R; Silva AF; Batatinha JA; Sobrado LF; Machado AD; Varone BB; Nearing BD; Belardinelli L; Verrier RL
Heart Rhythm; 2014 Oct; 11(10):1827-35. PubMed ID: 24953379
[TBL] [Abstract][Full Text] [Related]
35. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study.
Heidt MC; Vician M; Stracke SK; Stadlbauer T; Grebe MT; Boening A; Vogt PR; Erdogan A
Thorac Cardiovasc Surg; 2009 Aug; 57(5):276-80. PubMed ID: 19629889
[TBL] [Abstract][Full Text] [Related]
36. n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillators.
Christensen JH; Riahi S; Schmidt EB; Mølgaard H; Kirstein Pedersen A; Heath F; Cosedis Nielsen J; Toft E
Europace; 2005 Jul; 7(4):338-44. PubMed ID: 15944091
[TBL] [Abstract][Full Text] [Related]
37. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs.
Sarrazin JF; Comeau G; Daleau P; Kingma J; Plante I; Fournier D; Molin F
J Am Coll Cardiol; 2007 Oct; 50(15):1505-12. PubMed ID: 17919572
[TBL] [Abstract][Full Text] [Related]
38. Prevention and termination of beta-adrenergic agonist-induced arrhythmias by free polyunsaturated fatty acids in neonatal rat cardiac myocytes.
Kang JX; Leaf A
Biochem Biophys Res Commun; 1995 Mar; 208(2):629-36. PubMed ID: 7695617
[TBL] [Abstract][Full Text] [Related]
39. [Influence of ω-3 PUFAs on predictors of sudden cardiac death in patients with Q-wave myocardial infarction].
Logacheva IV; Barantseva NG; Vinokurova ES
Kardiologiia; 2012; 52(12):17-23. PubMed ID: 23237436
[TBL] [Abstract][Full Text] [Related]
40. Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion.
Hiura N; Wakatsuki T; Yamamoto T; Nishikado A; Oki T; Ito S
J Cardiovasc Pharmacol; 2001 Nov; 38(5):729-36. PubMed ID: 11602819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
